These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34835135)

  • 21. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.
    Zedan HT; Yassine HM; Al-Sadeq DW; Liu N; Qotba H; Nicolai E; Pieri M; Bernardini S; Abu-Raddad LJ; Nasrallah GK
    Sci Rep; 2022 Nov; 12(1):19020. PubMed ID: 36347859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus.
    Matusali G; Colavita F; Lapa D; Meschi S; Bordi L; Piselli P; Gagliardini R; Corpolongo A; Nicastri E; Antinori A; Ippolito G; Capobianchi MR; Castilletti C; Inmi Covid-Laboratory Team
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33920222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera.
    Ahn MJ; Kang JA; Hong SM; Lee KS; Kim DH; Song D; Jeong DG
    Biochem Biophys Res Commun; 2023 Feb; 646():8-18. PubMed ID: 36696754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2.
    Müller K; Girl P; von Buttlar H; Dobler G; Wölfel R
    J Virol Methods; 2021 Jun; 292():114122. PubMed ID: 33705832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
    Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
    Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
    Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies.
    James J; Rhodes S; Ross CS; Skinner P; Smith SP; Shipley R; Warren CJ; Goharriz H; McElhinney LM; Temperton N; Wright E; Fooks AR; Clark TW; Brookes SM; Brown IH; Banyard AC
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33924168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring.
    Cristiano A; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S; Nuccetelli M
    Clin Immunol; 2022 Jan; 234():108918. PubMed ID: 34971839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers.
    Infantino M; Manfredi M; Stacchini L; Cosma C; Grossi V; Lari B; Russo E; Amedei A; Benucci M; Veneziani F; Casprini P; Catalano CM; Cirrincione G; Bonaccorsi G; Pompetti A
    Clin Chem Lab Med; 2022 May; 60(6):934-940. PubMed ID: 35303766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
    Gavriatopoulou M; Terpos E; Malandrakis P; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
    Br J Haematol; 2022 Jan; 196(2):356-359. PubMed ID: 34528249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
    Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Saxton M; Piantadosi A; Waggoner JJ; Douek DC; Rouphael N; Wrammert J; Suthar MS
    Cell Rep Med; 2022 Feb; 3(2):100529. PubMed ID: 35233550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
    Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
    Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
    Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
    PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods.
    Banga Ndzouboukou JL; Zhang YD; Fan XL
    Curr Med Sci; 2021 Dec; 41(6):1052-1064. PubMed ID: 34935114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
    Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.